Showing 1 - 11 results of 11 for search 'David M. O'Malley', query time: 0.05s
Refine Results
-
1
-
2
-
3
-
4
-
5
Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II? by Monica D. Levine, David M. O'Malley, Paulina J. Haight, Leigha Senter, Vincent Wagner, Kristin L. Bixel, David E. Cohn, Larry J. Copeland, Casey M. Cosgrove, Eric M. McLaughlin, Floor J. Backes
Published 2023-04-01
Article -
6
Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancer by Rachael N. Piver, Vincent M. Wagner, Monica D. Levine, Floor J. Backes, Laura J. Chambers, David E. Cohn, Larry J. Copeland, Casey M. Cosgrove, Christa I. Nagel, David M. O'Malley, Kristin L. Bixel
Published 2023-04-01
Article -
7
Wound complications following vulvar excision for nonmalignant lesionsAJOG Global Reports at a Glance by Glenn P. Boyles, MD, Ashlee M. Weaver, MD, David E. Cohn, MD, Floor J. Backes, MD, Larry J. Copeland, MD, Kristin L. Bixel, MD, Jeffrey M. Fowler, MD, David M. O'Malley, MD, Casey M. Cosgrove, MD
Published 2021-11-01
Article -
8
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA tr... by Maria-Pilar Barretina-Ginesta, Bradley J. Monk, Sileny Han, Bhavana Pothuri, Annika Auranen, Dana M. Chase, Domenica Lorusso, Charles Anderson, Sophie Abadie-Lacourtoisie, Noelle Cloven, Elena I. Braicu, Amnon Amit, Andrés Redondo, Ruchit Shah, Nehemiah Kebede, Carol Hawkes, Divya Gupta, Tatia Woodward, David M. O’Malley, Antonio González-Martín
Published 2022-09-01
Article -
9
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable... by Lucy Gilbert, Ana Oaknin, Prafull Ghatage, Rebecca Kristeleit, Wei Guo, Sharad Ghamande, Valentina Boni, Jubilee Brown, Xinwei Han, Vanessa Samouëlian, Ellie Im, Renaud Sabatier, Anna V Tinker, David M O’malley, Bhavana Pothuri, Cara Mathews, Jennifer Veneris, Tao Duan, Linda Duska, Joshua Press, Charles Leath III, Sybil Zildjian
Published 2022-01-01
Article -
10
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease... by Ana Oaknin, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Leary, Robert W. Holloway, Margarita Amenedo Gancedo, Peter C. Fong, Jeffrey C. Goh, David M. O’Malley, Deborah K. Armstrong, Susana Banerjee, Jesus García‐Donas, Elizabeth M. Swisher, Terri Cameron, Lara Maloney, Sandra Goble, Jonathan A. Ledermann, Robert L. Coleman
Published 2021-10-01
Article -
11
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) by Elizabeth M. Swisher, Tanya T. Kwan, Amit M. Oza, Anna V. Tinker, Isabelle Ray-Coquard, Ana Oaknin, Robert L. Coleman, Carol Aghajanian, Gottfried E. Konecny, David M. O’Malley, Alexandra Leary, Diane Provencher, Stephen Welch, Lee-may Chen, Andrea E. Wahner Hendrickson, Ling Ma, Prafull Ghatage, Rebecca S. Kristeleit, Oliver Dorigo, Ashan Musafer, Scott H. Kaufmann, Julia A. Elvin, Douglas I. Lin, Setsuko K. Chambers, Erin Dominy, Lan-Thanh Vo, Sandra Goble, Lara Maloney, Heidi Giordano, Thomas Harding, Alexander Dobrovic, Clare L. Scott, Kevin K. Lin, Iain A. McNeish
Published 2021-05-01
Article